Lightstone Ventures
@LightstoneVC
Followers
103
Following
1
Statuses
46
Dedicated to empowering entrepreneurs with the resources and guidance needed to bring their innovative therapeutics to patients.
Joined August 2021
Please join us in welcoming H. Martin Seidel, Ph.D., to the Lightstone team as Advisor. Dr. Seidel brings over 30 years of experience across R&D and Business Development in both pharma and biotech to our team. We look forward to working with you!
0
0
0
Congratulations to Brendan Kelly, PhD, on his promotion to Principal at Lightstone Ventures! As a core member of our investment team, we celebrate Brendan’s leadership and contributions across our portfolio. We look forward to continuing our exciting work together!
0
0
0
We welcome Ken Mills as CEO and member of the Board of Directors for @tagworkspharma as the company expects to embark on its next phase of growth and enter the clinic in 2025 with its lead antibody-drug conjugate program, TGW101.
We're excited to announce Ken Mills has been appointed our new CEO and that Marc Robillard will continue as CSO & Board member. We look forward to working to bring our Click-to-Release platform and lead ADC program for solid tumors into the clinic in 2025.
0
0
0
Lightstone portfolio company @VoltaMedical announced positive results from their TAILORED-AF trial, comparing AI-assisted ablation procedure with the conventional treatment for persistent atrial fibrillation patients. Learn more about what was presented:
0
0
1
Congrats to @cerevance, who announced the closing of their Series B-1 Extension financing round. Lightstone is a proud fund partner, and we look forward to company updates as they progress their pipeline of therapies for CNS diseases. Read more:
We’re pleased to announce the addition of $47M to our Series B-1 Extension to advance our CVN424 therapy for the treatment of PD into a Phase 3 clinical trial and to support our robust pipeline of CNS treatments. Read more here:
0
0
0
Welcome José-Alain Sahel, M.D., to Lightstone, joining us as an advisor. A distinguished professor and leader in the Ophthalmology and Neuroscience space, Dr. Sahel’s deep knowledge will play a key role in supporting new and existing portfolio companies.
0
0
1
Congratulations to Jingjing Wang, Ph.D. on her promotion to Vice President at Lightstone! As a core member of our investment team, we look forward to exciting things to come as we continue our work together.
0
0
1
Congratulations to @RelievantMed, that has developed and commercialized the Intracept® Procedure, their FDA-cleared treatment for chronic #vertebrogenic pain, on being acquired by @bostonsci! Great news and great for patients. Learn more here:
Relievant is now Boston Scientific. Follow @bostonsci to stay up to date as we advance pain management solutions as part of Neuromodulation at Boston Scientific. Learn more here:
0
0
1
Exciting news from @cerevance, who dosed the first patient in their ASCEND Phase 2 clinical study of CVN424 for the treatment of individuals with Parkinson’s Disease. We look forward to future updates! Full press release:
0
0
1
Today, the launch of 65LAB was announced, a company creation vehicle designed to advance drug discovery & new therapeutics companies in Singapore. As a proud founding partner, we look forward to the potential patient impact of these discoveries. Read more:
0
0
0
Today, @AlxOncology shared encouraging positive interim Phase 2 data from their ASPEN-06 clinical trial evaluating evorpacept, for the treatment of advanced HER2-positive gastric cancer. Full press release here:
ALX Oncology today announced positive prespecified interim Phase 2 data from its ASPEN-06 clinical trial:
0
0
1
Sharing an exciting update from @cerevance, who recently announced that the first patient has been dosed in their Phase 1 study evaluating safety and tolerability of CVN293, for the treatment of #ALS and #Alzheimers. Full press release:
We’re pleased to announce that the first subject has been dosed in our Phase 1 clinical study evaluating CVN293, a selective inhibitor designed to modulate neuroinflammation for the treatment of ALS and Alzheimer’s disease. Read the release to learn more:
0
0
1
Congrats @RelievantMed, whose agreement to be acquired by @bostonsci was announced. The company’s therapy, the Intracept® Procedure, is their FDA-cleared treatment for chronic #vertebrogenic pain. Great news and great for patients! Learn more here:
0
0
0
Congratulations to @NimbusTx, on the closing of their $210 million private financing! Lightstone is a proud fund partner, and we look forward to updates as the company advances their pipeline in immunology, cancer and metabolic disease. Learn more:
We’re excited to announce a $210 million private financing to advance our next wave of tech-enabled small molecule medicines. Learn more:
0
0
0
Congrats to @Cerevance for being named one of @FierceBiotech’s 2023 #Fierce15 biotech companies. We’re looking forward to seeing more great accomplishments from Cerevance in the future!
We’re thrilled to announce that @FierceBiotech has named us a #Fierce15 biotech company of 2023. It is an honor to be acknowledged within this outstanding array of industry experts, and a testament to the groundbreaking work we are doing at Cerevance:
0
0
1
Congrats to @FIRE1_HF on successfully implanting the first U.S. patients with its FIRE1™ System for remote heart failure monitoring in a study that will assess the Company’s technology to improve outcomes for heart failure patients. Learn more:
We are in the US! Another great milestone for the FIRE1 team in its mission to help people with heart failure live their normal lives, thanks to all our docs across the US for making this happen and our National PI @NirUrielMD
0
1
3
Congrats to @Tagworkspharma, on the closing of their Series A financing! Lightstone is a proud fund partner, and we look forward to updates as the company advances their lead ADC program, TGW101, and their proprietary Click-to-Release platform. Learn more:
We’re excited to announce that we’ve raised $65 Million in Series A financing to advance a pipeline of Click-to-Release Therapeutics !
0
0
2
Lightstone portfolio company, @RelievantMed, recently announced the publication of three-year pooled results from the #Intracept Procedure, demonstrating long-term pain relief and reduced opioid use for patients with vertebrogenic pain. Learn more:
A new study in Interventional Pain Medicine details 3-year pooled outcomes from the #Intracept Procedure that demonstrate long-term pain relief and reduced opioid use in chronic #vertebrogenic low back pain patients. Read our press release to learn more:
0
0
1
This Thursday at #BIO2023, Lightstone Partner Christina Isacson, will discuss the role of health systems within the commercialization of new therapies alongside fellow industry experts. Panel details here:
Investment leaders, including Matthias Kleinz, EVP of @UPMCEnterprises, will discuss why health systems are taking a greater role in commercialization of biotech and therapeutic startups in the upcoming @IAmBiotech panel on 6/7. Learn more:
0
2
3
Lightstone portfolio company, @VoltaMedical, announced that the @US_FDA has cleared Volta AF-Xplorer™, an AI companion designed for the assessment of complex AF and atrial tachycardia procedures. Great work and great for patients! Learn more here:
0
0
0